Go Pro
NASDAQ:ALP

Portage Biotech Q4 2026 Earnings Report

Portage Biotech logo
$5.58 -0.03 (-0.53%)
As of 09/25/2026 04:00 PM Eastern

Portage Biotech EPS Results

Actual EPS
$23.75
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Portage Biotech Revenue Results

Actual Revenue
$0.05 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Portage Biotech Announcement Details

Quarter
Q4 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Portage Biotech Earnings Headlines

Alpha Compute Regains Full Compliance with Nasdaq Listing Rules
Portage Biotech (NASDAQ:ALP) Insider Fiorenzo Villani Purchases 10,000 Shares
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
Portage Biotech (NASDAQ:ALP) Insider Buys $17,273.25 in Stock
See More Portage Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Portage Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Portage Biotech and other key companies, straight to your email.

About Portage Biotech

Portage Biotech (NASDAQ:ALP) is a clinical-stage biotechnology company focused on developing immuno-oncology treatments designed to stimulate the immune system to target and eliminate cancer cells. Its research has centered on therapies involving invariant natural killer T (iNKT) cells, a specialized immune-cell population that may help generate targeted antitumor responses.

The company’s pipeline has included investigational therapies intended for use in solid tumors, including approaches that combine immune-cell activation with mechanisms designed to improve the tumor microenvironment and enhance treatment response. As a development-stage biotechnology company, Portage’s products remain subject to clinical testing and regulatory review and are not established commercial therapies.

Portage Biotech is incorporated in the British Virgin Islands and has pursued a geographically distributed research and development strategy through collaborations and affiliated biotechnology businesses. Publicly available company information identifies the business as Portage Biotech, Inc.; however, its commonly reported Nasdaq symbol has been PRTG rather than ALP. Leadership and pipeline details may change as the company advances its programs and updates its corporate structure.

View Portage Biotech Profile